Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$176.6m

Capricor Therapeutics Management

Management criteria checks 4/4

Capricor Therapeutics' CEO is Linda Marbán, appointed in Jan 2010, has a tenure of 14.42 years. total yearly compensation is $747.32K, comprised of 29.5% salary and 70.5% bonuses, including company stock and options. directly owns 0.63% of the company’s shares, worth $1.11M. The average tenure of the management team and the board of directors is 12.3 years and 10.6 years respectively.

Key information

Linda Marbán

Chief executive officer

US$747.3k

Total compensation

CEO salary percentage29.5%
CEO tenure14.4yrs
CEO ownership0.6%
Management average tenure12.3yrs
Board average tenure10.6yrs

Recent management updates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Recent updates

Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

May 08
Here's Why Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO May Have Their Pay Bumped Up

Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

Apr 19
Benign Growth For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Underpins Stock's 26% Plummet

We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Apr 16
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate

Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Feb 03
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip In Price Shows Sentiment Is Matching Revenues

Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Dec 13
Is Capricor Therapeutics (NASDAQ:CAPR) In A Good Position To Invest In Growth?

Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

Aug 13
Here's Why We're Not Too Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Situation

A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Nov 03
A Look At The Fair Value Of Capricor Therapeutics, Inc. (NASDAQ:CAPR)

Capricor Therapeutics GAAP EPS of -$0.29 misses by $0.03

Aug 10

Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

Feb 01
Companies Like Capricor Therapeutics (NASDAQ:CAPR) Are In A Position To Invest In Growth

We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Oct 14
We Think Capricor Therapeutics (NASDAQ:CAPR) Can Afford To Drive Business Growth

Capricor Therapeutics Announces Another 'Final' 12-Month P2 Duchenne Muscular Dystrophy Trial Result

Sep 25

Capricor Therapeutics slumps 9% on $75M stock offering

Jun 21

Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

May 16
Capricor Therapeutics (NASDAQ:CAPR) Is In A Good Position To Deliver On Growth Plans

When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Mar 13
When Will Capricor Therapeutics, Inc. (NASDAQ:CAPR) Turn A Profit?

Capricor signs intellectual property license for COVID-19 serology test platform

Feb 01

Capricor and Lonza tie up in DMD development

Jan 12

CEO Compensation Analysis

How has Linda Marbán's remuneration changed compared to Capricor Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

-US$24m

Dec 31 2023US$747kUS$221k

-US$22m

Sep 30 2023n/an/a

-US$29m

Jun 30 2023n/an/a

-US$29m

Mar 31 2023n/an/a

-US$29m

Dec 31 2022US$1mUS$210k

-US$29m

Sep 30 2022n/an/a

-US$27m

Jun 30 2022n/an/a

-US$25m

Mar 31 2022n/an/a

-US$23m

Dec 31 2021US$2mUS$200k

-US$20m

Sep 30 2021n/an/a

-US$18m

Jun 30 2021n/an/a

-US$18m

Mar 31 2021n/an/a

-US$17m

Dec 31 2020US$2mUS$150k

-US$14m

Sep 30 2020n/an/a

-US$11m

Jun 30 2020n/an/a

-US$9m

Mar 31 2020n/an/a

-US$7m

Dec 31 2019US$229kUS$157k

-US$8m

Sep 30 2019n/an/a

-US$9m

Jun 30 2019n/an/a

-US$12m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$377kUS$233k

-US$15m

Sep 30 2018n/an/a

US$374k

Jun 30 2018n/an/a

US$2m

Mar 31 2018n/an/a

US$2m

Dec 31 2017US$602kUS$233k

US$2m

Compensation vs Market: Linda's total compensation ($USD747.32K) is below average for companies of similar size in the US market ($USD1.55M).

Compensation vs Earnings: Linda's compensation has been consistent with company performance over the past year.


CEO

Linda Marbán (61 yo)

14.4yrs

Tenure

US$747,315

Compensation

Dr. Linda Marbán, Ph.D. Co-founded Capricor Therapeutics, Inc. (also known as Capricor, Inc). in 2005 and also has been its Chief Executive Officer since 2010 and serves as its President. Dr. Marbán has be...


Leadership Team

NamePositionTenureCompensationOwnership
Frank Litvack
Executive Chairman of the Board12.4yrsUS$759.55k0.42%
$ 739.6k
Linda Marbán
Co-Founder14.4yrsUS$747.32k0.63%
$ 1.1m
Anthony Bergmann
CFO & Corporate Treasurer6.4yrsUS$730.85k0.0075%
$ 13.2k
Karen Krasney
Executive VP12.3yrsUS$740.77k0.063%
$ 111.3k
Kristi A. Elliott
Chief Science Officerno datano datano data
Catherine Kelleher
Consultantno datano datano data

12.3yrs

Average Tenure

64.5yo

Average Age

Experienced Management: CAPR's management team is seasoned and experienced (12.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Frank Litvack
Executive Chairman of the Board12.4yrsUS$759.55k0.42%
$ 739.6k
Linda Marbán
Co-Founder10.6yrsUS$747.32k0.63%
$ 1.1m
George Dunbar
Independent Director10.6yrsUS$211.13k0.033%
$ 58.6k
Earl Collier
Independent Director10.6yrsUS$222.37k0.18%
$ 315.6k
David Musket
Independent Director10.6yrsUS$237.36k0.17%
$ 304.1k
Francesco Muntoni
Member of Scientific Advisory Boardno datano datano data
Pat Furlong
Member of Scientific Advisory Boardno datano datano data
Eugenio Mercuri
Member of Scientific Advisory Boardno datano datano data
Craig McDonald
Member of Scientific Advisory Boardno datano datano data
Oscar Mayer
Member of Scientific Advisory Boardno datano datano data
Michelle Eagle
Member of Scientific Advisory Boardno datano datano data
Michael Taylor
Member of Scientific Advisory Board6.4yrsno datano data

10.6yrs

Average Tenure

68yo

Average Age

Experienced Board: CAPR's board of directors are seasoned and experienced ( 10.6 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.